1. Home
  2. PAHC vs CDXC Comparison

PAHC vs CDXC Comparison

Compare PAHC & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAHC
  • CDXC
  • Stock Information
  • Founded
  • PAHC 1946
  • CDXC 1999
  • Country
  • PAHC United States
  • CDXC United States
  • Employees
  • PAHC N/A
  • CDXC N/A
  • Industry
  • PAHC Biotechnology: Pharmaceutical Preparations
  • CDXC Medicinal Chemicals and Botanical Products
  • Sector
  • PAHC Health Care
  • CDXC Health Care
  • Exchange
  • PAHC Nasdaq
  • CDXC Nasdaq
  • Market Cap
  • PAHC 682.5M
  • CDXC 546.9M
  • IPO Year
  • PAHC 2014
  • CDXC N/A
  • Fundamental
  • Price
  • PAHC $24.46
  • CDXC $6.82
  • Analyst Decision
  • PAHC Sell
  • CDXC Strong Buy
  • Analyst Count
  • PAHC 3
  • CDXC 2
  • Target Price
  • PAHC $19.00
  • CDXC $8.00
  • AVG Volume (30 Days)
  • PAHC 174.8K
  • CDXC 2.8M
  • Earning Date
  • PAHC 11-06-2024
  • CDXC 10-31-2024
  • Dividend Yield
  • PAHC 1.96%
  • CDXC N/A
  • EPS Growth
  • PAHC N/A
  • CDXC N/A
  • EPS
  • PAHC 0.43
  • CDXC 0.02
  • Revenue
  • PAHC $1,046,762,000.00
  • CDXC $91,668,000.00
  • Revenue This Year
  • PAHC $21.75
  • CDXC $18.64
  • Revenue Next Year
  • PAHC $12.67
  • CDXC $20.72
  • P/E Ratio
  • PAHC $56.92
  • CDXC $351.56
  • Revenue Growth
  • PAHC 7.17
  • CDXC 9.95
  • 52 Week Low
  • PAHC $9.49
  • CDXC $1.32
  • 52 Week High
  • PAHC $25.98
  • CDXC $7.58
  • Technical
  • Relative Strength Index (RSI)
  • PAHC 56.80
  • CDXC 70.03
  • Support Level
  • PAHC $24.23
  • CDXC $6.22
  • Resistance Level
  • PAHC $25.98
  • CDXC $7.58
  • Average True Range (ATR)
  • PAHC 0.90
  • CDXC 0.63
  • MACD
  • PAHC 0.08
  • CDXC 0.17
  • Stochastic Oscillator
  • PAHC 60.21
  • CDXC 81.42

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About CDXC ChromaDex Corporation

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

Share on Social Networks: